Regeneron Pharmaceuticals is a biotechnology company focused on the discovery, development, and commercialization of innovative medicines for serious diseases. Its core products include EYLEA, a treatment for eye diseases, and REGEN-COV, a COVID-19 therapy. The company operates primarily in the healthcare sector, with major revenue sources stemming from product sales and collaborations. Regeneron invests heavily in research and development to expand its portfolio and pipeline of therapies.
The investment profile of Regeneron Pharmaceuticals is more aligned with growth investors due to its focus on innovation and potential for future revenue increases. The company offers a modest dividend yield, appealing to those seeking some income, but its primary appeal lies in growth potential. The stock may be more suitable for medium to long-term investors who can tolerate volatility.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-06-03 02:51 | Hold | Sell | Weak momentum and fundamentals raise significant risk. |
| 2026-05-24 02:48 | Sell | Hold | Weak momentum and fundamentals raise significant risk. |
| 2026-05-16 02:34 | Hold | Sell | Weak fundamentals and negative momentum raise concerns. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-05-19 10:43 | Canaccord Genuity | Target Lowered | 1057 → 875 | 629.68 |
| 2026-05-18 18:48 | Wolfe Research | Target Lowered | 900 → 860 | 629.36 |
| 2026-05-18 12:40 | Evercore ISI | Target Lowered | 875 → 825 | 619.84 |
